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Erythrocytosis associated with a novel missense
mutation in the BPGM gene
Erythropoiesis is stimulated by the oxygen-regulated gly-
coprotein, erythropoietin (Epo). Erythrocytosis is a condi-
tion characterized by increased red cell mass and character-
istically elevated hematocrit (Hct) and hemoglobin (Hb)
concentration.1 Table 1 summarizes its causes. When fully
investigated (including genetic screening for known muta-
tions), there remain a number of patients in whom no
cause could be found, who are currently described as hav-
ing idiopathic erythrocytosis. A large proportion of these
have elevated or inappropriately normal (for the Hb level)
serum Epo levels, suggesting an abnormality in oxygen
sensing. Investigations have shown that several cases pre-
viously diagnosed as idiopathic erythrocytosis can now be
attributed to mutations in genes involved in oxygen sens-
ing.1
Here, we describe a patient who, following screening for
known mutations in VHL, EGLN1 and EPAS1, was classi-
fied as having sporadic idiopathic erythrocytosis with
raised Epo levels. This Caucasian man presented at the age
of 27 with fatigue. His past medical and family history were
unremarkable. He was a non-smoker with a 16-unit alco-
hol intake per week. He was found to have a high Hb con-
centration of 193 g/L, a red cell count of 6.53×1012/L, mean
corpuscular volume (MCV) of 89.7 fL, mean cell hemoglo-
bin (MCH) of 29.9 pg, MCHC of 333 g/L, Hct of 0.586 l/L,
white cell count (WCC) of 6.5×109/L (with a normal differ-
ential) and platelets of 167×109/L. Red cell mass was 146%
predicted. Vitamin B12 was 380 ng/L, folate was 8.9 mcg/L
and ferritin was 58 mcg/L. Liver function tests revealed a
slightly raised AST of 61 U/L and ALT 101 U/L. These sub-
sequently normalized following significant weight loss but
the Hb and Hct remained elevated. An abdominal ultra-
sound was normal. Hb electrophoresis was normal and
revealed: HbF 0.5% and HbA2 2.8%. Serum Epo was 15.9
mIU/mL (normal range 2.5-10.5 mIU/mL). Arterial blood
gas analysis found a carboxyhemoglobin of 1.2% and a P50,
the partial pressure of oxygen at which 50% of Hb is satu-
rated with oxygen, was calculated at 23.91 mmHg (normal
range 27-33 mmHg; control sample 32.7 mmHg), suggest-
ing a mild leftward shift in the Hb-oxygen dissociation
curve. He commenced low-dose aspirin and was treated
with venesection every 3-6 months, aiming for Hct of less
than 0.5 l/L.  Five years following his initial presentation,
his disease etiology was re-visited. In view of a high likeli-
hood for a genetic etiology owing to his extreme pheno-
type of early onset, whole-genome sequencing (WGS) was
undertaken searching for causal mutations. Informed con-
sent was obtained and procedures were performed in
agreement with the Declaration of Helsinki. 
Whole-genome sequencing was performed as part of the
WGS500 Project, whereby 500 individuals with a variety of
medical conditions of suspected genetic origin were
sequenced to assess the clinical utility of WGS. It was con-
ducted on the Illumina HiSeq2000 at a 30x sequencing
depth. Reads were mapped to the human reference
genome (hg19) using STAMPY,2 identification of alleles and
variants was performed using the in-house Platypus soft-
ware3 and annotated using a pipeline based on
ANNOVAR.4 We searched for heterozygous or homozy-
gous variants in candidate genes: HIF1A, EPAS1 (HIF2A),
HIF3A, ARNT (HIF1B), HIF1AN (FIH), EGLN1 (PHD2),
EGLN2 (PHD1), EGLN3 (PHD3), VHL, EPO, EPOR, JAK2,
HBB, HBA1, HBA2 and BPGM; or for rare coding mutations
in any gene. Given the large number of genes involved in
oxygen sensing and the regulation of erythropoiesis, and
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Table 1. Causes of erythrocytosis.
Primary erythrocytosis (typically low Epo levels)
Congenital Acquired
Epo receptor mutations Polycythemia vera 
(including JAK2mutations)
Secondary erythrocytosis (high or normal Epo levels)
Congenital (inherited) Acquired (Epo-mediated)
Defects in oxygen-sensing pathway: Systemic hypoxia:
VHLmutations (e.g. Chuvash polycythemia) Chronic lung disease
EGLN1 (PHD2) mutations Right-to-left cardiopulmonary vascular shunts
EPAS1 (HIF2A) mutations Smoker’s erythrocytosis
Nocturnal hypoventilation syndromes 
(e.g. obstructive sleep apnea)
Other congenital defects High altitude
High-oxygen affinity Hb Local hypoxia:
Bisphosphoglycerate mutase deficiency Renal artery stenosis
Renal cysts (polycystic kidney disease)
Post-renal transplant erythrocytosis
Pathological Epo production (tumors)
Brain (cerebellar hemangioblastoma, meningioma)
Renal cell carcinoma
Hepatocellular carcinoma
Phechromocytoma
Drug-associated:
Erythropoietin/androgen administration
Adapted from McMullin.1
the growing evidence of new genes interacting with the
HIF factors, WGS was considered an appropriate and most
informative investigation, compared with traditional meth-
ods of DNA sequencing which are impractical, lengthy and
labor-intensive. 
A single novel heterozygous non-synonymous SNV was
identified in the gene bisphosphoglycerate mutase (BPGM),
at chr7:134346528. This was a G269A substitution, pre-
dicting the substitution of arginine at the evolutionarily
conserved residue 90 with histidine (R90H). This mutation
was not detected in any other samples sequenced in the
WGS500 Project, nor was it reported in the 1000 Genomes
analysis. No other candidate gene coding variants were
found in the patient’s genome; this was validated by Sanger
sequencing. To establish whether this arose de novo, we
screened the patient’s parents and found that the mutation
was inherited from his mother, who was also heterozygous
(Figure 1). She had a [Hb] of 150 g/L and serum Epo level of
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Table 2. Results of BPGM and 2,3-BPG assays in red blood cells.
                                                                Patient                                 Patient’s                      Control             Healthy control
                                                            (index case)                               mother                   sample with              samples 
                                                                           At initial               At time of                                             comparable               (n=10)
                                                                        presentation      functional studies                                             [Hb]                                                                                                             
Hb (g/L)                                                                                193                              159                            155                                    157                    126.60 ± 19.04*
NR: 130 – 180 (Male), 
115 – 155 (Female)                                                               
BPGM (IU/g Hb)                                                                  NA                              3.62                           3.27                                   4.21                      4.99 ± 0.59*
2,3-BPG
(µmol/g Hb)                                                                         NA                              14.5                           11.3                                   18.7                     27.60 ± 6.75*
RBC (x1012/L)                                                                        6.5                               6.5                             5.2                                     5.2                       4.14 ± 0.64*
NR: 4.5 – 6.5 (Male),
3.9 – 5.6 (Female)                                                                 
WBC (x109/L)                                                                        6.5                               4.2                             7.0                                     6.3                       7.99 ± 5.10*
NR: 4.0 – 11.0                                                                          
Platelets (×109/L)                                                               167                              210                            230                                    177                   307.30 ± 148.85*
NR: 150 - 400                                                                            
Epo  (miU/mL)
NR: 2.5 – 10.5                                                                       15.9                              NA                             7.5                                     NA                                NA
*Mean ± SD. Note that at the time of functional studies the patient’s Hb is lower owing to the fact that he had already commenced therapy with venesection at 3-monthly inter-
vals.  BPGM was measured by the Schröter and Kalinowsky method, as modified by Beutler. Briefly, an equilibrium mixture of F-1,6-biP, GAP, DHAP, 1,3-BPG, NAD and NADH is
established. Addition of hemolysate containing BPGM causes the removal of 1,3-BPG, displacement of the GAP/1,3-BPG equilibrium and the reduction of NAD to NADH, which
is monitored by the increase in absorbance at 340 nm. The 2,3-BPG was measured by a modification of the method of Krimsky. Briefly, an equilibrium mixture of PEP, enolase,
2-PGA, PGAM-1 and 3-PGA is formed. Addition of red cell extract containing 2,3-BPG, the obligatory co-factor for PGAM-1 activity, causes depletion of PEP, which is monitored
by the decrease in absorbance at 240 nm.
Figure 1. DNA sequence analysis detected a heterozygous G>A sub-
stitution at nucleotide c.269, in the patient and his mother but not
his father. This predicts the substitution of arginine at residue 90
with histidine (R90H).
Figure 2. Structural effects. Inspection of the crystal structure of
human BPGM (RCSB PDB id: 2HHJ5) indicated that R90 is poten-
tially involved in hydrogen bonds with carbonyl groups from E156
and W115, stabilizing the structure of the protein and the active
site pocket (note proximity to phosphate group of 2,3-BPG). Figure
produced using PyMOL (The PyMOL Molecular Graphics System,
Schrödinger, LLC).
Patient
Father
Mother
W115 E156
R90H
2,3-BPG
7.5 mIU/mL. A Polyphen score of 1.0 predicted that the
R90H mutation is deleterious. Inspection of the 3D struc-
ture of BPGM suggests that replacement of arginine (R90)
with histidine would potentially disrupt hydrogen bonds
with backbone carbonyl groups, negatively affecting pro-
tein folding and stability (Figure 2). The functional effects of
the mutation were confirmed by showing significantly
lower levels of BPGM and its product 2,3-BPG in the red
blood cells of both the patient and his mother (Table 2).
BPGM was measured by the method Schröter and
Kalinowsky, modified by Beutler,6 and 2,3-BPG by a modi-
fication of the method of Krimsky,7 as explained in Table 2. 
Bisphosphoglycerate mutase is the enzyme responsible
for the synthesis of 2,3-BPG (from 1,3-BPG) in red blood
cells.8 Normally 2,3-BPG is present at high concentrations
(~5 mM) in red blood cells and binds the deoxy form of Hb
to reduce its affinity for oxygen.9 BPGM deficiency leads to
reduced levels of 2,3-BPG, resulting in a leftward shift in
the hemoglobin-oxygen dissociation curve. Less available
oxygen induces Epo production to stimulate red cell pro-
duction and hence the development of erythrocytosis.
Defects in BPGM have been associated both with hemolyt-
ic anemia10 and erythrocytosis.11,12 In 1978, Rosa et al.
reported the first case of a 42-year old man with complete
deficiency of BPGM and erythrocytosis.11 His Hb concen-
tration was 190 g/L, his erythrocyte 2,3-BPG was below
3% of normal values and he had a low P50.  His sister also
had complete BPGM deficiency and excessive erythrocyto-
sis and they were both compound heterozygous with an
SNV on one allele at codon 89 (corresponding to codon 90
in the current reference genome) causing an arginine to cys-
teine substitution (R89C) resulting in low levels of an
abnormal (inactive) BPGM protein and a deletion of
nucleotide 205 or 206 (codon 19) on the other allele, trans-
lating an aberrant product.13 In contrast, his son and daugh-
ter, who were heterozygous only for the R89C mutation,
had intermediate phenotypes with partial BPGM deficiency
and modest erythrocytosis.13 Garel et al. reproduced the
same functional defect in BPGM as the natural arginine-to-
cysteine mutant in artificial mutants, Arg89Gly and
Arg89Ser, produced by site-directed mutagenesis, giving
evidence that indeed the arginine at this position is func-
tionally important in the enzyme’s function.14 Only one
other BPGM mutation, a homozygous Arg62Gln, was
found in a male patient with erythrocytosis, who had con-
current G6-phosphate dehydrogenase deficiency and evi-
dence of consanguinity in his family.12 Indeed, mutations in
BPGM are exceedingly rare. Recently, Bento et al.
sequenced 70 cases of idiopathic erythrocytosis, including
sequencing of BPGM in cases with high Epo and no BPGM
mutations were identified.15
Interestingly, the same amino acid residue (i.e. arginine at
codon 90) is affected, as in previous cases of
erythrocytosis.13 However, in our patient a different base
substitution occurs, resulting in a novel amino acid substi-
tution of arginine to histidine as opposed to arginine to cys-
teine in previous cases. This reinforces the findings of Garel
et al.14 that the arginine residue at 90 is important for the
function/stability of BPGM. Our patient, initially thought
to be a sporadic case, inherited this mutation from his
mother, who is also heterozygous. This is of interest for
two reasons. One is that all previous erythrocytosis cases
associated with BPGM mutations at the arginine 90 residue
were not sporadic but rather were found in families with an
autosomal dominant pattern of inheritance. The second is
that, while the mother is also heterozygous for this muta-
tion she is not polycythemic and has Epo levels within the
normal range. One explanation for this could be that there
is a second ‘hit’ in the patient leading to compound het-
erozygosity as in Lemarchandel et al.;13 however, WGS did
not reveal any additional mutations/deletions in BPGM.
Alternatively, the explanation could be that of a variable
penetrance of the disease-causing mutation, consistent
with the phenotypes and patterns of inheritance of the
family members in Lemarchandel et al.13 There, the index
case and his sister, both compound heterozygotes, had
complete BPGM deficiency and excessive erythrocytosis.
His children, heterozygotes, had an intermediate pheno-
type, and his parents, at least one of whom was heterozy-
gous for the arginine-to-cysteine mutation, were both
healthy. Furthermore, while our patient’s mother is not
polycythemic, her Hb lies at the upper end of the normal
range and there is evidence of dysfunction in her red blood
cells with low BPGM activity and 2,3-BPG levels, reinforc-
ing the view that this mutation is functional. Given that
heterozygous individuals, both in our study and in that of
Lemarchandel et al.13 have intermediate levels of BPGM
activity and 2,3-BPG levels, i.e. much higher than com-
pound heterozygotes, the ‘variable penetrance’ observed
may simply be the result of variable effects reduced 2,3-
BPG has on hemoglobin and the induction of erythro-
poiesis. It is also possible that the variable effects of the het-
erozygous BPGM mutation relates to different expression
ratios of wild-type versusmutant BPGM in different individ-
uals. 
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